The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.

OTEZLA DELIVERS PROVEN AND SUSTAINED EFFICACY1

Sustained PASI response up to 32 weeks1,a

Created with Highcharts 8.0.4OTEZLA 30 mg BIDCrossover to OTEZLA 30 mg BIDPlacebo020406080100Highcharts.com
Week 16
(n = 501)
(n = 247)
Week 32
(n = 425)
(n = 216)
Mean Percent Improvement in
PASI Score From Baseline
62%
62%

aESTEEM 1 study; full analysis set, data as observed.

OTEZLA improves skin clearance in biologic-naïve patients, with response maintained up to 2 years1,2

See the OTEZLA difference

Real patients, real pictures.*

Actual patient with psoriasis before treatment with OTEZLA® (apremilast). Please see full Important Safety Information.

Baseline

Actual patient with a decrease in PASI score after 16 weeks of treatment with OTEZLA® (apremilast). Please see full Important Safety Information.

Week 16 PASI-45 result

Individual results may vary.

Actual patient with a 62% decrease in PASI score after 32 weeks of treatment with OTEZLA® (apremilast). Please see full Important Safety Information.

Week 32 PASI-68 result

Individual results may vary.

*Photos taken from the ESTEEM clinical trial program, which evaluated OTEZLA 30 mg BID in patients with active plaque psoriasis.

BID, twice daily; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; PASI, Psoriasis Area and Severity Index.

OTEZLA DELIVERS RAPID AND SUSTAINED EFFICACY IN BIOLOGIC-NAÏVE PATIENTS2,3†

Sustained PASI improvement up to 2 years2,3,a

aLIBERATE study. Data as observed among patients with a value at the time point indicated, with no imputation for missing values.

OTEZLA improves skin clearance in biologic-naïve
patients, with response maintained up to 2 years2,3

References:

  1. Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73:37-49.
  2. Data on file, Amgen Inc.
  3. Reich K, Gooderham M, Bewley A, et al. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study. J Eur Acad Dermatol Venereol. 2018;32(3):397-402.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 54 countries*
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Singapore

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Kuwait

  • Taiwan

  • UAE

  • South Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil

  • Malaysia

  • Oman

  • Saudi Arabia

On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).

Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.

For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.